|pSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. As of June 30, 2011, the Company is focused on the treatment of chronic eye diseases utilizing its cored technology systems, Durasert and BioSilicon. Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). Its product candidate ILUVIEN, for the treatment of diabetic macular edema (DME) is under review by the United States Food and Drug Administration (FDA). The Company’s two FDA-approved products provide sustained release drug delivery to treat other back-of-the-eye diseases. An investigator-sponsored trial is ongoing for an injectable bioerodible insert delivering latanoprost designed to treat glaucoma and ocular hypertension and an investigator-sponsored Investigational New Drug opened for an injectable insert of the same design as ILUVIEN designed to treat posterior uveitis.|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.